作者: BADRINATH R. KONETY , JAMES A. EASTHAM , VICTOR E. REUTER , PETER T. SCARDINO , S. MACHELE DONAT
DOI: 10.1097/01.JU.0000108122.36893.5A
关键词:
摘要: ABSTRACTPurpose: We determined the feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy in locally advanced (stage T3 or greater) and/or high risk tumors (Gleason 8 to 10 serum prostate specific antigen (PSA) greater than 20 ng/ml).Materials and Methods: Enrollment criteria included clinical stage T1 2 with any Gleason grade PSA ng/ml, 4 grade, biopsy PSA. All patients received hormonal during chemotherapy (4 cycles paclitaxel carboplatin estramustine) followed by prostatectomy. Nerve sparing was decided on an individual basis a nerve graft offered those who underwent unilateral bilateral resection. Perioperative morbidity, mortality delayed complications were assessed.Results: A total 36 enrolled. After less 39% of...